Skip to content
OpenCapital
Get started

Geron GERN AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's afs and trading securities - unrealized loss position (>=12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's AFS and trading securities - unrealized loss position (>=12 months) fair value?
Geron (GERN) reported AFS and trading securities - unrealized loss position (>=12 months) fair value of $0 in Q1 2026.
How has Geron's AFS and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Geron's AFS and trading securities - unrealized loss position (>=12 months) fair value decreased by 100.0% year-over-year, from $2M to $0.